- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05340712
Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation
Evaluation of the Efficacy of a New Specific Infant Formula With a Prebiotic and Probiotics in Case of Functional Constipation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anne-Sophie Garreau
- Phone Number: 0033-155372222
- Email: as.garreau@novalac.com
Study Contact Backup
- Name: Caroline Thevret, Dr.
- Phone Number: 0033-155372222
- Email: c.thevret@novalac.com
Study Locations
-
-
-
Napoli, Italy, 80131
- Recruiting
- University of Naples "Federico II"
-
Contact:
- Annamaria Staiano, Prof.
- Phone Number: 0039 0817462679
- Email: staiano@unina.it
-
Principal Investigator:
- Annamaria Staiano, Prof.
-
Napoli, Italy, 80138
- Not yet recruiting
- University of Campania Luigi Vanvitelli
-
Contact:
- Caterina Strisciuglio, Prof.
- Email: caterinastrisciuglio@hotmail.it
-
Principal Investigator:
- Caterina Strisciuglio, Prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Selection Criteria:
Infants presenting with constipation according to modified Rome IV criteria, i.e. they must present with 1 month the following:
- Infants without spontaneous stools or with at least one painful or hard spontaneous bowel movement per week AND
At least one of the following:
- Two and fewer spontaneous defecations per week
- History of excessive stool retention
- History of large-diameter stools
Non-selection Criteria (non-exhaustive list):
- Preterm birth (<34 weeks of gestational age)
- Exclusively or partially breastfed infants within 3 days prior to visit V-1
- Infants with organic causes of constipation (e.g. coeliac disease, paediatric intestinal pseudo-obstruction, hypothyroidism, spina bifida, anorectal malformation or Hirschsprung's disease) or constipation secondary to endocrine, metabolic, neurologic or autoimmune disorders, surgery or drugs.
- Infants on laxative treatment
- Infants taking drugs that are known to affect gastrointestinal motility as well as any probiotic supplements
- Infants treated with antibiotics
- Infants with a known allergy to one of the formula ingredients (e.g. cow's milk proteins…)
- Infants with anaemia who have been prescribed an oral iron supplement as treatment
- Infants participating in another trial
- Infants presenting with any other situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the infant
Inclusion Criteria:
- Infants having completed the selection period and still compliant with non-selection criteria
- Infants being constipated according to modified Rome IV criteria based on information recorded in parents' diary during the week preceding visit V0 (inclusion visit)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IT formula
The test product (IT formula) is an infant formula based on cow's milk proteins containing a high level of lactose, a prebiotic, a high concentration of magnesium and a mix of probiotics.
|
New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
|
PLACEBO_COMPARATOR: Standard formula
The control product is a standard infant formula based on cow's milk proteins containing usual lactose and magnesium content, no prebiotic nor probiotic.
|
Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hard stool consistency or painful defecation
Time Frame: 30 days
|
Proportion of hard or painful stools per total number of spontaneous bowel movements by participant. A spontaneous bowel movement is defined as described in outcome 2. Stool consistency will be evaluated based on the Brussels Infant and Toddler Stool Scale (BITSS). BITSS is a reliable instrument to assess stools of non-toilet trained children. It consists of color photographs of nappies containing stools from infants and toddlers categorized as hard, formed, loose, or watery (Huysentruyt et al., 2019). The consistency and painful defecation of each stool will be assessed by parents at Day 30. |
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total and spontaneous defecation frequency
Time Frame: 30, 60, 90 and 120 days
|
Spontaneous bowel movement is defined as a bowel movement not produced by the use of rescue medication. Stools occurring within 24h after the use of rescue medication will not be considered spontaneous. If 2 stools occur within less than 1 hour, only 1 stool will be considered (Koppen et al., 2018). Defecation frequency will be assessed by parents by recording the time of each stool during the week preceding each visit. |
30, 60, 90 and 120 days
|
Stool consistency
Time Frame: 30, 60, 90 and 120 days
|
Parents will record the consistency of every stool the week preceding each visit as described in the outcome 1 using the BITSS scale (Brussels Infant and Toddler Stool Scale) which consists of 4 stools consistency categories (hard, formed, loose, or watery ; Huysentruyt et al., 2019)
|
30, 60, 90 and 120 days
|
Painful defecation
Time Frame: 30, 60, 90 and 120 days
|
Painful defecation will be evaluated by parents for each stool during the week preceding each visit (Yes/No).
|
30, 60, 90 and 120 days
|
Excessive stool retention
Time Frame: 30, 60, 90 and 120 days
|
"Excessive stool retention" is defined as "the infant withholding stools".
It will be evaluated by parents at each visit (presence/absence).
|
30, 60, 90 and 120 days
|
Large diameter stools
Time Frame: 30, 60, 90 and 120 days
|
Large diameter stools will be assessed by parents at each visit using the picture of the largest stool in the BITSS as an example of the large diameter stool (presence/absence).
|
30, 60, 90 and 120 days
|
Treatment success
Time Frame: 30, 60, 90 and 120 days
|
Treatment success is defined as no longer meeting the modified Rome IV criteria for functional constipation, i.e. the treatment will be considered as a success if the infant does not meet more than one of the following criteria per week during the week preceding each visit:
|
30, 60, 90 and 120 days
|
Rescue medication use
Time Frame: 30, 60, 90 and 120 days
|
The frequency of use, type and dosage of rescue medication will be assessed by parents during the whole study.
|
30, 60, 90 and 120 days
|
Weight
Time Frame: 30, 60, 90 and 120 days
|
Weight will be expressed in kg and in z scores according to the World Health Organization (WHO) Child Growth Standards.
|
30, 60, 90 and 120 days
|
Height
Time Frame: 30, 60, 90 and 120 days
|
Height will be expressed in cm and in z scores according to the WHO Child Growth Standards.
|
30, 60, 90 and 120 days
|
Head circumference
Time Frame: 30, 60, 90 and 120 days
|
Head circumference will be expressed in cm and in z scores according to the WHO Child Growth Standards.
|
30, 60, 90 and 120 days
|
BMI
Time Frame: 30, 60, 90 and 120 days
|
BMI will be expressed in value and z scores according to the WHO Child Growth Standards.
|
30, 60, 90 and 120 days
|
Adverse events
Time Frame: Through study completion, i.e. 67 days or 127 days if participation to the optional follow-up period
|
Any untoward medical condition occurring during the study in an infant receiving study products regardless of a causal relationship with the product or not will be considered an adverse event and reported as such.
This definition includes events occurring from the moment the parents have signed the Informed Consent form (day -7) up until the study end (or early termination).
|
Through study completion, i.e. 67 days or 127 days if participation to the optional follow-up period
|
Nutritional status
Time Frame: 0 and 60 days
|
Nutritional status will be assessed based on the evaluation of specific blood biological markers (albumin, creatinine, urea, hemoglobin, sodium, potassium, chloride).
|
0 and 60 days
|
Crying time
Time Frame: 30, 60, 90 and 120 days
|
Daily crying duration will be assessed by parents on 3 days in the week preceding each visit.
|
30, 60, 90 and 120 days
|
Regurgitations
Time Frame: 30, 60, 90 and 120 days
|
The number of regurgitation episodes, the volume of regurgitation and regurgitation severity will be assessed by parents on 3 days in the week preceding each visit.
Regurgitation severity will be assessed through the Vandenplas score ranging from 0 (=less than 2 regurgitation episodes / day) to 6 (=regurgitation of the complete volume after each feeding).
|
30, 60, 90 and 120 days
|
Sleep quality
Time Frame: 30, 60, 90 and 120 days
|
Sleep quality will be evaluated by parents at each visit by asking them if their child's sleep was quiet or agitated.
|
30, 60, 90 and 120 days
|
Sleep time satisfaction
Time Frame: 30, 60, 90 and 120 days
|
Sleep time satisfaction will be evaluated by parents at each visit (Yes/No).
|
30, 60, 90 and 120 days
|
Parents' quality of life (QoL)
Time Frame: 30, 60, 90 and 120 days
|
Parents' QoL will be assessed based on a questionnaire adapted from the Parental Opinions of Pediatric Constipation (POOPC) scale (Silverman et al., 2015).
Questions from this scale were chosen based on their relevance to constipated infants.
This questionnaire is composed of 4 items, i.e.
Burden/Worry, Family, Treatment and Social.
Each question is scored on a scale of 1 (=Strongly Disagree) to 5 (=Strongly Agree) with higher scores indicating that infant's constipation greatly affects parents' QoL.
The total score is calculated by summing the scores of all individual question, ranging from 15 to 75 where a score of 15 indicates that infant's constipation does not affect parents' QoL whereas a score of 75 indicates that parents' QoL is extremely affected by infant's constipation.
|
30, 60, 90 and 120 days
|
Parents' satisfaction
Time Frame: 30, 60, 90 and 120 days
|
Parents' adequate relief will be assessed at each visit (Yes/No).
|
30, 60, 90 and 120 days
|
Gut microbiota composition
Time Frame: 0 and 60 days
|
Gut microbiota composition will be analyzed by 16S rRNA gene sequencing from stool samples.
|
0 and 60 days
|
Short-chain fatty acids (SCFAs)
Time Frame: 0 and 60 days
|
SCFAs will be measured in stool samples by gas chromatography/mass spectrometry (GC/MS).
|
0 and 60 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Annamaria Staiano, Prof., Federico II University
- Study Chair: Marc Benninga, Prof., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Principal Investigator: Caterina Strisciuglio, Prof., University of Campania "Luigi Vanvitelli"
Publications and helpful links
General Publications
- Huysentruyt K, Koppen I, Benninga M, Cattaert T, Cheng J, De Geyter C, Faure C, Gottrand F, Hegar B, Hojsak I, Miqdady M, Osatakul S, Ribes-Koninckx C, Salvatore S, Saps M, Shamir R, Staiano A, Szajewska H, Vieira M, Vandenplas Y; BITSS working group. The Brussels Infant and Toddler Stool Scale: A Study on Interobserver Reliability. J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):207-213. doi: 10.1097/MPG.0000000000002153.
- Koppen IJN, Saps M, Lavigne JV, Nurko S, Taminiau JAJM, Di Lorenzo C, Benninga MA. Recommendations for pharmacological clinical trials in children with functional constipation: The Rome foundation pediatric subcommittee on clinical trials. Neurogastroenterol Motil. 2018 Apr;30(4):e13294. doi: 10.1111/nmo.13294. Epub 2018 Jan 30.
- Silverman AH, Berlin KS, Di Lorenzo C, Nurko S, Kamody RC, Ponnambalam A, Mugie S, Gorges C, Sanghavi R, Sood MR. Measuring Health-Related Quality of Life With the Parental Opinions of Pediatric Constipation Questionnaire. J Pediatr Psychol. 2015 Sep;40(8):814-24. doi: 10.1093/jpepsy/jsv028. Epub 2015 Apr 2.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UP2021-02-FALCON
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Constipation
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Huazhong University of Science and TechnologyWuhan Union Hospital, China; Guangzhou University of Traditional Chinese Medicine and other collaboratorsUnknownFunctional Constipation | Functional DiarrheaChina
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Chulalongkorn UniversityNot yet recruitingFunctional ConstipationThailand
-
Min-Tze LIONGDeyang People's HospitalRecruiting
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional ConstipationUnited States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
-
Gelesis, Inc.Not yet recruitingConstipation - Functional
-
Wageningen University and ResearchAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); FrieslandCampina... and other collaboratorsRecruitingFunctional ConstipationNetherlands
-
University of AlexandriaCompletedFunctional ConstipationEgypt
-
The First Affiliated Hospital of Xiamen UniversityEnrolling by invitationFunctional ConstipationChina
Clinical Trials on new infant formula
-
Jovie USA, LLCIQVIA RDS Inc.; ObvioHealthCompleted
-
Laboratorios OrdesaUnknownInfant DevelopmentSpain
-
Bobbie Baby, IncRecruitingHealthy GrowthUnited States
-
Nutricia North AmericaMedical College of Wisconsin; Wake Forest University Health Sciences; Nemours... and other collaboratorsCompletedCongenital Heart Disease | Growth FailureUnited States
-
Danone NutriciaNutricia Early Life Nutrition (Shanghai) Co., LtdCompletedHealthy InfantsChina
-
Junlebao Dairy Group Co., Ltd.Merieux NutriSciences (China)Recruiting
-
Abbott NutritionCompleted
-
Abbott NutritionCompleted
-
Société des Produits Nestlé (SPN)University College, LondonCompletedGrowth | Infant FormulaUnited Kingdom